News and Trends 12 Dec 2022
OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data
OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B-…